Pediatrix Medical Group (MD) Projected to Announce Earnings on Thursday

Pediatrix Medical Group (NYSE:MD) will likely be releasing its Q3 2026 results before the market opens on Thursday, October 29th. Analysts expect the company to post earnings of $0.65 per share and revenue of $498.18 million for the quarter. Investors may visit the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Thursday, October 29, 2026 at 9:00 AM ET.

Pediatrix Medical Group (NYSE:MD) last issued its quarterly earnings results on Tuesday, August 4th. The company reported $0.63 EPS for the quarter, topping analysts’ consensus estimates of $0.59 by $0.04. Pediatrix Medical Group had a net margin of 8.96% and a return on equity of 20.05%. The firm had revenue of $487.78 million for the quarter, compared to analyst estimates of $478.49 million. During the same quarter in the prior year, the firm earned $0.53 EPS. The business’s revenue for the quarter was up 4.1% compared to the same quarter last year. On average, analysts expect Pediatrix Medical Group to post $2.17 EPS for the current fiscal year and $2.23 EPS for the next fiscal year.

Pediatrix Medical Group Stock Performance

NYSE MD opened at $28.07 on Thursday. Pediatrix Medical Group has a 52-week low of $16.82 and a 52-week high of $28.29. The company has a fifty day moving average of $26.55 and a 200-day moving average of $24.86. The company has a market capitalization of $2.28 billion, a P/E ratio of 13.43 and a beta of 0.61. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.32 and a current ratio of 1.32.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on MD. Wall Street Zen raised Pediatrix Medical Group from a “buy” rating to a “strong-buy” rating in a research note on Sunday, September 13th. Truist Financial upped their price objective on Pediatrix Medical Group from $23.00 to $28.00 and gave the stock a “hold” rating in a report on Tuesday, July 14th. Jefferies Financial Group lowered Pediatrix Medical Group from a “buy” rating to a “hold” rating and increased their price objective for the company from $27.00 to $28.00 in a research report on Wednesday, August 19th. UBS Group increased their price objective on Pediatrix Medical Group from $25.00 to $28.00 and gave the company a “neutral” rating in a research report on Thursday, August 6th. Finally, Deutsche Bank Aktiengesellschaft reissued a “hold” rating and set a $25.00 price objective on shares of Pediatrix Medical Group in a report on Wednesday, August 5th. One equities research analyst has rated the stock with a Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $26.60.

About Pediatrix Medical Group

Pediatrix Medical Group, Inc provides specialized physician-led healthcare services for women, infants and children. The company’s clinical offerings include neonatal and perinatal care, maternal-fetal medicine, pediatric medical subspecialties, pediatric hospitalist services and related services delivered in partnership with hospitals and healthcare systems.

Pediatrix-affiliated physicians and advanced practice providers generally work in hospital-based settings, including neonatal intensive care units, delivery rooms, pediatric units and outpatient practices.